🇺🇸 FDA
Pipeline program

20 mg VEC-162

VP-VEC-162-3101

Phase 3 small_molecule completed

Quick answer

20 mg VEC-162 for Insomnia is a Phase 3 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Insomnia
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials